Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Gilead Sciences ( (GILD) ) has provided an announcement.
On April 28, 2026, Gilead Sciences, Inc. completed its acquisition of Arcellx, Inc., consolidating a collaboration centered on anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR T-cell therapy for multiple myeloma that uses a novel D-Domain binder and holds multiple expedited U.S. FDA designations. The deal gives Gilead full control of anito-cel within Kite Oncology and removes future profit-sharing, milestone and royalty obligations tied to the program.
Gilead paid $115 in cash per Arcellx share plus a $5 non-transferable contingent value right, implying equity value of about $7.8 billion, after a tender offer that closed with roughly 77.2% of shares tendered and a follow-on merger that made Arcellx a wholly owned subsidiary to be delisted from Nasdaq. The transaction, accounted for as an asset acquisition, is expected to reduce Gilead’s 2026 GAAP and non-GAAP diluted EPS by around $5.57–$5.67 and be modestly dilutive in 2026–27 but accretive from 2028 onward, contingent on regulatory approval and commercial success of anito-cel, with CVR payments tied to achieving at least $6.0 billion in cumulative global net sales by end-2029.
The most recent analyst rating on (GILD) stock is a Buy with a $160.00 price target. To see the full list of analyst forecasts on Gilead Sciences stock, see the GILD Stock Forecast page.
Spark’s Take on GILD Stock
According to Spark, TipRanks’ AI Analyst, GILD is a Outperform.
The score is driven primarily by strong financial performance (TTM profitability rebound and consistently high free cash flow) and constructive technical momentum (price above key moving averages with healthy MACD/RSI). Earnings-call guidance and sentiment are supportive due to continued base-business and HIV/prevention growth, though policy and cell-therapy headwinds temper upside. Valuation is reasonable but not clearly cheap at ~22.5x earnings with a ~2.1% dividend yield.
To see Spark’s full report on GILD stock, click here.
More about Gilead Sciences
Gilead Sciences, Inc. is a global biopharmaceutical company focused on developing innovative medicines for life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Through its Kite Oncology unit, it is building an oncology portfolio spanning antibody-drug conjugates, small molecules and cell therapies, and operates in more than 35 countries from its headquarters in Foster City, Calif.
The company has also outlined major capital commitments in the United States, including a planned $32 billion investment announced in 2025 to expand its domestic footprint. This strategy is intended to support the next phase of drug discovery, manufacturing capacity, job creation and public health preparedness while continuing to fund global expansion so patients worldwide can access its treatments.
Average Trading Volume: 6,574,696
Technical Sentiment Signal: Buy
Current Market Cap: $161.9B
See more data about GILD stock on TipRanks’ Stock Analysis page.